Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

186 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Results of NOPHO ALL2008 treatment for patients aged 1-45 years with acute lymphoblastic leukemia.
Toft N, Birgens H, Abrahamsson J, Griškevičius L, Hallböök H, Heyman M, Klausen TW, Jónsson ÓG, Palk K, Pruunsild K, Quist-Paulsen P, Vaitkeviciene G, Vettenranta K, Åsberg A, Frandsen TL, Marquart HV, Madsen HO, Norén-Nyström U, Schmiegelow K. Toft N, et al. Among authors: vettenranta k. Leukemia. 2018 Mar;32(3):606-615. doi: 10.1038/leu.2017.265. Epub 2017 Aug 18. Leukemia. 2018. PMID: 28819280
In vitro cellular drug resistance adds prognostic information to other known risk-factors in childhood acute lymphoblastic leukemia.
Lönnerholm G, Thörn I, Sundström C, Frost BM, Flaegstad T, Heyman M, Jonsson OG, Harila-Saari A, Madsen HO, Porwit A, Schmiegelow K, Söderhäll S, Wesenberg F, Vettenranta K, Larsson R, Forestier E. Lönnerholm G, et al. Among authors: vettenranta k. Leuk Res. 2011 Apr;35(4):472-8. doi: 10.1016/j.leukres.2010.09.001. Epub 2010 Oct 18. Leuk Res. 2011. PMID: 20961616
Risk group assignment differs for children and adults 1-45 yr with acute lymphoblastic leukemia treated by the NOPHO ALL-2008 protocol.
Toft N, Birgens H, Abrahamsson J, Bernell P, Griškevičius L, Hallböök H, Heyman M, Holm MS, Hulegårdh E, Klausen TW, Marquart HV, Jónsson OG, Nielsen OJ, Quist-Paulsen P, Taskinen M, Vaitkeviciene G, Vettenranta K, Åsberg A, Schmiegelow K. Toft N, et al. Among authors: vettenranta k. Eur J Haematol. 2013 May;90(5):404-12. doi: 10.1111/ejh.12097. Epub 2013 Apr 2. Eur J Haematol. 2013. PMID: 23461707
Toxicity profile and treatment delays in NOPHO ALL2008-comparing adults and children with Philadelphia chromosome-negative acute lymphoblastic leukemia.
Toft N, Birgens H, Abrahamsson J, Griškevičius L, Hallböök H, Heyman M, Klausen TW, Jónsson ÓG, Palk K, Pruunsild K, Quist-Paulsen P, Vaitkeviciene G, Vettenranta K, Asberg A, Helt LR, Frandsen T, Schmiegelow K. Toft N, et al. Among authors: vettenranta k. Eur J Haematol. 2016 Feb;96(2):160-9. doi: 10.1111/ejh.12562. Epub 2015 Apr 24. Eur J Haematol. 2016. PMID: 25867866
Parents' and Adolescents' Preferences for Intensified or Reduced Treatment in Randomized Lymphoblastic Leukemia Trials.
Tulstrup M, Larsen HB, Castor A, Rossel P, Grell K, Heyman M, Abrahamsson J, Söderhäll S, Åsberg A, Jonsson OG, Vettenranta K, Frandsen TL, Albertsen BK, Schmiegelow K; Nordic Society of Paediatric Haematology, and Oncology (NOPHO). Tulstrup M, et al. Among authors: vettenranta k. Pediatr Blood Cancer. 2016 May;63(5):865-71. doi: 10.1002/pbc.25887. Epub 2015 Dec 31. Pediatr Blood Cancer. 2016. PMID: 26717887 Clinical Trial.
Children with low-risk acute lymphoblastic leukemia are at highest risk of second cancers.
Nielsen SN, Eriksson F, Rosthoej S, Andersen MK, Forestier E, Hasle H, Hjalgrim LL, Aasberg A, Abrahamsson J, Heyman M, Jónsson ÓG, Pruunsild K, Vaitkeviciené GE, Vettenranta K, Schmiegelow K. Nielsen SN, et al. Among authors: vettenranta k. Pediatr Blood Cancer. 2017 Oct;64(10). doi: 10.1002/pbc.26518. Epub 2017 May 13. Pediatr Blood Cancer. 2017. PMID: 28500740
Individualized 6-mercaptopurine increments in consolidation treatment of childhood acute lymphoblastic leukemia: A NOPHO randomized controlled trial.
Tulstrup M, Frandsen TL, Abrahamsson J, Lund B, Vettenranta K, Jonsson OG, Marquart HVH, Albertsen BK, Heyman M, Schmiegelow K. Tulstrup M, et al. Among authors: vettenranta k. Eur J Haematol. 2018 Jan;100(1):53-60. doi: 10.1111/ejh.12979. Epub 2017 Nov 9. Eur J Haematol. 2018. PMID: 28983968 Clinical Trial.
Low burden of minimal residual disease prior to transplantation in children with very high risk acute lymphoblastic leukaemia: The NOPHO ALL2008 experience.
Ifversen M, Turkiewicz D, Marquart HV, Winiarski J, Buechner J, Mellgren K, Arvidson J, Rascon J, Körgvee LT, Madsen HO, Abrahamsson J, Lund B, Jonsson OG, Heilmann C, Heyman M, Schmiegelow K, Vettenranta K. Ifversen M, et al. Among authors: vettenranta k. Br J Haematol. 2019 Mar;184(6):982-993. doi: 10.1111/bjh.15761. Epub 2019 Jan 24. Br J Haematol. 2019. PMID: 30680711 Free article.
Relapse risk following truncation of pegylated asparaginase in childhood acute lymphoblastic leukemia.
Gottschalk Højfeldt S, Grell K, Abrahamsson J, Lund B, Vettenranta K, Jónsson ÓG, Frandsen TL, Wolthers BO, Marquart HV, Vaitkeviciene G, Lepik K, Heyman M, Schmiegelow K, Albertsen BK. Gottschalk Højfeldt S, et al. Among authors: vettenranta k. Blood. 2021 Apr 29;137(17):2373-2382. doi: 10.1182/blood.2020006583. Blood. 2021. PMID: 33150360 Free article. Clinical Trial.
186 results